KR20220119425A - 항염증 특성을 갖는 카르복시 유도체 - Google Patents

항염증 특성을 갖는 카르복시 유도체 Download PDF

Info

Publication number
KR20220119425A
KR20220119425A KR1020227024819A KR20227024819A KR20220119425A KR 20220119425 A KR20220119425 A KR 20220119425A KR 1020227024819 A KR1020227024819 A KR 1020227024819A KR 20227024819 A KR20227024819 A KR 20227024819A KR 20220119425 A KR20220119425 A KR 20220119425A
Authority
KR
South Korea
Prior art keywords
methyl
acrylic acid
oxadiazol
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227024819A
Other languages
English (en)
Korean (ko)
Inventor
마이클 리암 쿠케
데이비드 커즌
매튜 콜린 토르 파이프
토마스 마이클 와프
살레 아메드
알레시오 드 시몬
배리 존 테오발드
Original Assignee
시트릭스 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시트릭스 테라퓨틱스 리미티드 filed Critical 시트릭스 테라퓨틱스 리미티드
Publication of KR20220119425A publication Critical patent/KR20220119425A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
KR1020227024819A 2019-12-23 2020-12-23 항염증 특성을 갖는 카르복시 유도체 Pending KR20220119425A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP19219531 2019-12-23
EP19219531.1 2019-12-23
EP20162545.6 2020-03-11
EP20162545 2020-03-11
EP20189623 2020-08-05
EP20189623.0 2020-08-05
EP20205768.3 2020-11-04
EP20205768 2020-11-04
PCT/GB2020/053357 WO2021130492A1 (en) 2019-12-23 2020-12-23 Carboxy derivatives with antiinflammatory properties

Publications (1)

Publication Number Publication Date
KR20220119425A true KR20220119425A (ko) 2022-08-29

Family

ID=74104118

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227024819A Pending KR20220119425A (ko) 2019-12-23 2020-12-23 항염증 특성을 갖는 카르복시 유도체

Country Status (30)

Country Link
US (1) US12617762B2 (enExample)
EP (2) EP4081511B3 (enExample)
JP (2) JP7679384B2 (enExample)
KR (1) KR20220119425A (enExample)
CN (1) CN115066418B (enExample)
AU (1) AU2020412853A1 (enExample)
BR (1) BR112022011933A2 (enExample)
CA (2) CA3161424C (enExample)
CL (1) CL2022001722A1 (enExample)
CO (1) CO2022008652A2 (enExample)
CR (1) CR20220300A (enExample)
DK (1) DK4081511T6 (enExample)
EC (1) ECSP22049370A (enExample)
ES (1) ES2987014T7 (enExample)
FI (1) FI4081511T6 (enExample)
HR (1) HRP20241378T4 (enExample)
HU (1) HUE068571T2 (enExample)
IL (1) IL293982B2 (enExample)
JO (1) JOP20220162A1 (enExample)
LT (1) LT4081511T (enExample)
MA (1) MA58170B1 (enExample)
MD (1) MD4081511T2 (enExample)
MX (1) MX2022007846A (enExample)
PE (1) PE20221584A1 (enExample)
PH (1) PH12022551546A1 (enExample)
PL (1) PL4081511T6 (enExample)
RS (1) RS66019B1 (enExample)
SI (1) SI4081511T2 (enExample)
TW (1) TWI891696B (enExample)
WO (1) WO2021130492A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240115616A (ko) * 2023-01-19 2024-07-26 대한민국(질병관리청 국립보건연구원장) 뎅기바이러스 감염에 의한 질환의 예방 또는 치료용 약학적 조성물

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL287444B2 (en) 2019-04-30 2024-09-01 Sitryx Therapeutics Ltd Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
EP4192821A1 (en) 2020-08-05 2023-06-14 Sitryx Therapeutics Limited Alpha,beta unsaturated methacrylic esters with anti-inflammatory properties
US12678419B2 (en) 2020-10-27 2026-07-14 Sitryx Therapeutics Limited Compounds
WO2022229617A1 (en) * 2021-04-26 2022-11-03 Sitryx Therapeutics Limited 2-methylene-4-oxo-butanoic acid drivatives for the treatment of inflammation
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2022269251A1 (en) * 2021-06-22 2022-12-29 Sitryx Therapeutics Limited Acrylamide derivatives useful as anti-inflammatory agents
CN113499453B (zh) * 2021-07-20 2022-10-21 徐州医科大学 自噬抑制及抗炎联合温合光热诊疗剂及其制备方法与应用
WO2023017269A1 (en) 2021-08-11 2023-02-16 Sitryx Therapeutics Limited Derivatives of itaconic acid and their use as anti-inflammatory agents
WO2023247958A1 (en) 2022-06-22 2023-12-28 Sitryx Therapeutics Limited Oxadiazole derivatives, preparation process thereof and their use in treating inflammatory diseases
WO2024089421A1 (en) 2022-10-25 2024-05-02 Sitryx Therapeutics Limited Tetrazole derivatives
AU2023392783A1 (en) * 2022-12-15 2025-06-19 Sitryx Therapeutics Limited Substituted pyridines for use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response
CN115819186B (zh) * 2023-02-14 2023-05-16 广东银珠医药科技有限公司 一种3,5-二氯苯甲醇的新型制备方法
CN117205194A (zh) * 2023-05-10 2023-12-12 苏州大学 衣康酸或其衍生物在制备预防或治疗急性移植物抗宿主病药物中的应用
CN116725998A (zh) * 2023-07-20 2023-09-12 中国科学技术大学 特立氟胺在抑制nlrp3炎症小体活化中的应用
CN118812769B (zh) * 2024-07-02 2025-09-26 南京工业大学 一种衣康酰肼诱导的Janus结构聚合物表皮贴片电极及其制备方法
CN119792264B (zh) * 2025-03-14 2025-06-10 华中科技大学同济医学院附属同济医院 丁酰肼在制备预防或治疗copd的药物中的应用
CN120585811B (zh) * 2025-08-07 2026-01-06 华南理工大学 4-辛基衣康酸在制备改善肺动脉高压的药物中的应用
CN121668151A (zh) * 2026-02-11 2026-03-17 武汉大学人民医院（湖北省人民医院） 衣康酸类化合物在制备治疗视网膜动脉阻塞药物中的用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963672A1 (de) 1969-12-19 1971-06-24 Hoechst Ag Dithiophosphorsaeureester,ihre Herstellung und Anwendung als Schaedlingsbekaempfungsmittel
DE2047465A1 (de) 1970-09-26 1972-03-30 Farbwerke Hoechst AG, vorm Meister Lucius & Bruning, 6000 Frankfurt Neue Oxdiazole und Verfahren zu lh rer Herstellung
NL7413713A (nl) 1973-11-02 1975-05-07 Ciba Geigy Werkwijze voor het bereiden van nieuwe esters.
DE2805756A1 (de) 1978-02-10 1979-08-16 Bayer Ag N-azolylalkyl-aniline sowie verfahren zu ihrer herstellung
JPS6212776A (ja) 1985-07-10 1987-01-21 Taiho Yakuhin Kogyo Kk ロ−ダニン誘導体
EP0521622B1 (en) 1991-07-03 1997-08-13 PHARMACIA & UPJOHN COMPANY Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
EP0724573A1 (en) * 1993-10-20 1996-08-07 PHARMACIA & UPJOHN COMPANY Pyrimidinones as antiarthritic and anti-inflammatories
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
KR100538968B1 (ko) 1997-02-18 2006-07-11 후지 샤신 필름 가부시기가이샤 포지티브감광성조성물
US5965718A (en) 1997-10-24 1999-10-12 The Scripps Research Institute Analogs of sarcodictyin and eleutherobin
JP2001354625A (ja) 2000-04-12 2001-12-25 Dainippon Ink & Chem Inc 新規なイタコン酸エステル及びその製造方法
JP4102014B2 (ja) 2000-10-03 2008-06-18 富士フイルム株式会社 感光性平版印刷版
JP2004315791A (ja) 2003-03-28 2004-11-11 Tokyo Ohka Kogyo Co Ltd ジカルボン酸モノエステル化合物およびその製造方法ならびに重合体
TW201206429A (en) 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
US8637536B2 (en) * 2010-12-06 2014-01-28 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
MX386935B (es) 2013-03-14 2025-03-04 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
AU2014290368B2 (en) * 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
CN103923105B (zh) * 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
EP3416634A4 (en) 2016-02-15 2019-10-09 Artyomov, Maxim IMMUNOMODULATORY AGENTS AND METHOD FOR USE THEREOF
US20200375929A1 (en) 2017-08-14 2020-12-03 Washington University Methods and compositions for the treatment of diseases associated with cancer, inflammation, or immune response
WO2019066827A1 (en) 2017-09-27 2019-04-04 Intel Corporation CHARACTERISTICS AND APPROACHES TO GRID ASSISTANCE FOR ELECTRON BEAM DIRECT WRITE LITHOGRAPHY (EBDW)
EP3813815B1 (en) 2018-06-29 2026-01-28 Ergon Pharmaceuticals, LLC Compositions and methods of using itaconic acid derivatives
IL287444B2 (en) 2019-04-30 2024-09-01 Sitryx Therapeutics Ltd Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
US20200377510A1 (en) * 2019-05-30 2020-12-03 Auransa Inc. Derivatives of piperlongumine and uses thereof
CN110731955B (zh) 2019-10-28 2023-05-02 中山大学 衣康酸二甲酯在预防和治疗溃疡性结肠炎及其癌变中的应用
EP4192821A1 (en) 2020-08-05 2023-06-14 Sitryx Therapeutics Limited Alpha,beta unsaturated methacrylic esters with anti-inflammatory properties
EP4200275A2 (en) 2020-08-21 2023-06-28 Sitryx Therapeutics Limited Fumarate derivatives and their medical use
US12678419B2 (en) 2020-10-27 2026-07-14 Sitryx Therapeutics Limited Compounds
EP4237408A1 (en) 2020-10-29 2023-09-06 Sitryx Therapeutics Limited Itaconic acid derivatives
EP4237404A1 (en) 2020-10-29 2023-09-06 Sitryx Therapeutics Limited Novel compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240115616A (ko) * 2023-01-19 2024-07-26 대한민국(질병관리청 국립보건연구원장) 뎅기바이러스 감염에 의한 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
PL4081511T4 (pl) 2024-12-09
TWI891696B (zh) 2025-08-01
ES2987014T3 (es) 2024-11-13
EP4081511B3 (en) 2026-03-04
JP2025131581A (ja) 2025-09-09
BR112022011933A2 (pt) 2022-09-06
FI4081511T3 (fi) 2024-10-24
EP4081511A1 (en) 2022-11-02
TW202138356A (zh) 2021-10-16
WO2021130492A1 (en) 2021-07-01
AU2020412853A1 (en) 2022-05-26
PL4081511T6 (pl) 2026-06-01
DK4081511T3 (da) 2024-09-23
CR20220300A (es) 2022-08-23
PL4081511T3 (pl) 2024-11-25
FI4081511T6 (fi) 2026-06-09
CO2022008652A2 (es) 2022-07-19
CA3280359A1 (en) 2026-03-02
LT4081511T (lt) 2024-10-25
IL293982B1 (en) 2025-04-01
HUE068571T2 (hu) 2025-01-28
SI4081511T1 (sl) 2024-12-31
JOP20220162A1 (ar) 2023-01-30
EP4442319A2 (en) 2024-10-09
SI4081511T2 (sl) 2026-06-30
DK4081511T6 (da) 2026-05-26
HRP20241378T1 (hr) 2025-01-03
MA58170B1 (fr) 2024-10-31
PH12022551546A1 (en) 2023-05-03
US12617762B2 (en) 2026-05-05
CA3161424A1 (en) 2021-07-01
HRP20241378T4 (hr) 2026-06-19
MD4081511T2 (ro) 2025-01-31
ECSP22049370A (es) 2022-07-29
CA3161424C (en) 2025-10-21
JP7679384B2 (ja) 2025-05-19
US20230219907A1 (en) 2023-07-13
EP4081511B1 (en) 2024-07-31
JP2023508142A (ja) 2023-03-01
RS66019B1 (sr) 2024-11-29
CN115066418B (zh) 2025-09-05
IL293982A (en) 2022-08-01
CN115066418A (zh) 2022-09-16
EP4442319A3 (en) 2025-01-15
IL293982B2 (en) 2025-08-01
MX2022007846A (es) 2022-07-19
PE20221584A1 (es) 2022-10-06
ES2987014T7 (en) 2026-06-24
CL2022001722A1 (es) 2023-03-03

Similar Documents

Publication Publication Date Title
JP7679384B2 (ja) 抗炎症特性を有するカルボン酸誘導体
US12459908B2 (en) Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties
KR20220002952A (ko) 이타콘산 유도체, 및 염증성 질환 또는 바람직하지 않은 면역반응과 관련된 질환의 치료에서의 이의 용도
WO2022038365A2 (en) Novel compounds
WO2022090724A1 (en) Novel compounds
EP4237402A1 (en) Novel compounds
WO2022090723A1 (en) Itaconic acid derivatives
WO2022269251A1 (en) Acrylamide derivatives useful as anti-inflammatory agents
KR20250136325A (ko) 염증성 질환 또는 바람직하지 않은 면역 반응과 연관된 질환을 치료 또는 예방하는 데 사용하기 위한 치환된 피리딘
KR20250033235A (ko) 옥사디아졸 유도체, 그의 제조 방법 및 염증성 질환의 치료에 있어서의 그의 용도
EA048584B1 (ru) Карбоксипроизводные с противовоспалительными свойствами
HK40083255B (en) Carboxy derivatives with antiinflammatory properties
HK40083255A (en) Carboxy derivatives with antiinflammatory properties

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701